In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Complete revascularization on patients presenting with cardiogenic shock: real life data.

Session Poster Session 3

Speaker Hugo Miranda

Congress : Heart Failure 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease: Treatment, Revascularization
  • Session type : Poster Session
  • FP Number : P1796

Authors : I Almeida (Barreiro,PT), H Miranda (Barreiro,PT), H Santos (Barreiro,PT), J Chin (Barreiro,PT), C Sousa (Barreiro,PT), S Almeida (Barreiro,PT), J Tavares (Barreiro,PT)

I Almeida1 , H Miranda1 , H Santos1 , J Chin1 , C Sousa1 , S Almeida1 , J Tavares1 , 1Hospital N.S. Rosario - Barreiro - Portugal ,

On behalf: Portuguese Registry of Acute Coronary Syndrome - ProACS


Introduction: The CULPRIT-SHOCK trial showed that immediate multivessel percutaneous coronary intervention (PCI) increased the risk of death or severe renal failure at 30 days on patients (P) presenting with cardiogenic shock (CS).

Objective: Evaluation of prognostic impact of complete revascularization (CR) on P admitted with ST segment elevation myocardial infarction (STEMI) in CS and multivessel disease (MVD).

Material and methods: Retrospective analysis of P data admitted due to STEMI and CS and MVD at multicentric registry between 2000-2018. Compared demographic and clinical characteristics of P who were submitted to CR (group 1 – G1) versus who did not (group 2 – G2) and evaluated its prognostic impact.

Results: Admitted 7919 P with STEMI, which 295 (3.7%) on CS. 46.8% of the P on CS had MVD, 69.6% were submitted to CR. G1 P were younger (61±11 vs 73±12 years, p<0.001). The STEMI location was predominantly anterior (80%) in G1 and inferior in G2 (50%). The stablished timings symptoms start - reperfusion therapy and first medical contact - reperfusion were not statistically different between groups. 20% of G1 P did more than one coronarography during hospitalization. The anterior descendent was the artery more frequently involved in both groups (80 vs 89.8%) being the culprit lesion in 47.4% of G1 P and in 27.7% of G2 P, where the most frequently was the right coronary (43.4%, p <0.001). The majority of G1 P (95%) had 2-vessel disease; in G2 53.4% had 2-vessel disease and 46.6% 3-vessel disease (p<0.001).  All the G1 P did PCI; in G2, 96.6% did PCI and 3.4% had a hybrid technique (in 2.3% coronary artery bypass grafting planned after hospital discharge). Other interventions during hospitalization were needed, namely non-invasive ventilation (35 vs 21.6%), invasive ventilation (30 vs 34.1%), intra-aortic pump (20 vs 17%) and temporary pacemaker (5 vs 25%), not statistically significant. The stablished endpoints were reinfarction rate (5% between G1 P vs 0%), AHF (70 vs 83%), stroke (5.3 vs 0%) and in hospital death (35 vs 37.5%), not statistically significant.

Conclusion: Although the evaluated endpoints are different and measured at different timings, our results do not appear to follow the trends presented in CULPRIT-SHOCK trial probably as a result of the small sample size and the shorter follow up time.

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are